19 results about "Amino acid binding" patented technology

Aspects of the application provide methods of identifying and sequencing proteins, polypeptides, and amino acids, and compositions useful for the same. In some aspects, the application provides amino acid recognition molecules, such as amino acid binding proteins and fusion polypeptides thereof. In some aspects, the application provides amino acid recognition molecules comprising a shielding element that enhances photostability in polypeptide sequencing reactions.

The invention provides an application of polyphyllin VII in preparation of an Akt signaling pathway inhibitor targeting GRB2, the invention reveals that PPVII is specifically combined with GRB2 protein and regulates and controls the function of the GRB2 protein for the first time, the Akt pathway inhibition effect is exerted, and the molecular mechanism of PPVII is specifically shown as follows: molecular docking and dynamic simulation confirms that PPVII and an SH3 structural domain of GRB2 form a stable compound, and the stable compound is used for inhibiting the Akt pathway of the GRB2. And the key amino acid binding sites are Ile65, Gln157, Tyr160 and Phe182. Cell thermal transfer experiments (CETSA) show that PPVII can significantly enhance the thermal stability of GRB2 protein, surface plasmon resonance (SPR) determines the direct binding affinity KD = 58.5 [mu] M, functional research proves that PPVII inhibits an Akt signal channel through a GRB2 dependency mode, the polyphyllin VII is used as a GRB2 targeted inhibitor, and by specifically binding with an SH3 structural domain of GRB2 and inhibiting a downstream Akt signal channel, the polyphyllin VII can be used for inhibiting the Akt signal channel in the GRB2 targeted inhibitor. And a new strategy and a candidate compound are provided for intervention of related diseases.

The invention provides a preparation method of an amino acid liquid fertilizer, and relates to the technical field of amino acid liquid fertilizers. According to the preparation method of the amino acid liquid fertilizer, the amino acid liquid fertilizer is prepared from the following raw materials in parts by mass: 550-650 parts of a nutrient solution, 350-400 parts of liquid amino acid, 60-70 parts of boric acid, 50-60 parts of zinc sulfate and 5-6 parts of a root growth promoting agent. The amino acid is combined with the boric acid and the zinc sulfate, and then is combined with the root growth promoting agent, so that the liquid fertilizer capable of meeting the crop rooting requirement can be prepared, and the defects that the liquid fertilizer applied in the existing production is low in amino acid, boron and zinc content, cannot completely meet the requirements of crop growth and is short in fertilizer efficiency lasting period are overcome. Amino acid is used as a main material and matched with other boron and zinc elements to be fully dissolved, auxiliaries are added, crops can better absorb the amino acid, boron and zinc for use, the utilization rate is increased, plant growth is promoted, the crop yield is improved, and precise application of water and fertilizer integration is matched.

Provided is an amino acid recognition agent having improved binding properties, which is capable of obtaining more structural information from a polypeptide based on the kinetics of the on-off binding between the recognition agent and the polypeptide. The amino acid recognition agent may comprise an amino acid binding protein having an engineered binding pocket with one or more modifications relative to a homologous protein. Compared with an unmodified homologous protein binding pocket, the modified binding pocket can increase the number of interactions formed between the binding pocket and an amino acid ligand, and can increase the number of types of amino acid ligands capable of detecting binding compared with the unmodified homologous protein binding pocket. According to the present invention, the amino acid ligands of one or more types can be bound to one or more types of amino acid ligands, and can improve kinetics (e.g., KD, koff, kon) binding to one or more types of amino acid ligands, which advantageously increases the amount or confidence of structural information obtained from polypeptide analysis.

Obtained is: a method for efficiently producing a polypeptide containing a non-canonical amino acid; a method for incorporating a non-canonical amino acid into a polypeptide; a method for producing tRNA bound to a non-canonical amino acid; a non-canonical amino acid incorporation system; a material for use in these methods; or the like. Used is a method for producing a polypeptide containing a non-canonical amino acid, comprising: a step of contacting PylRS from an organism belonging to the order Methanomassiliicoccales or Thermoplasmatales with the non-canonical amino acid; and an incorporation step selected from step (a) of incorporating the non-canonical amino acid into the polypeptide with higher efficiency than in a case of using a cell-free protein synthesis system with PylRS of Methanosarcina mazei (MmPylRS) or step (b) of incorporating the non-canonical amino acid into the polypeptide with higher efficiency than in a case of using an Escherichia coli protein synthesis system with a vector carrying a gene for the PylRS under regulation by a glmS promoter or a case of using an Escherichia coli protein synthesis system with a vector carrying a gene for the PylRS under regulation by a glnS promoter. Alternatively, used is a non-canonical amino acid incorporation system containing highly concentrated PylRS from an organism belonging to the order Methanomassiliicoccales or Thermoplasmatales.

The invention provides a preparation method of a glycosylation modified casein-phenylalanine conjugate. The preparation method comprises the following steps: carrying out acid-base modification on casein, preparing glycosylation modified casein, conjugating the glycosylation modified casein and phenylalanine, purifying and freeze-drying. The casein is modified by the N-acetylglucosamine and the phenylalanine together, so that a new compound is formed. The monosaccharide, amino acid and casein composite system can significantly improve the stability and encapsulation efficiency of the Pickering emulsion through interfacial adsorption, steric hindrance, electrostatic repulsion and other mechanisms. Casein has a dissolution-condensation property under different pH values, so that the casein has a pH response switching characteristic. A composite system formed by combining the glycosylated modified casein and the amino acid can realize a responsive behavior through a specific enzyme. According to the invention, the preparation conditions of the Pickering emulsion are optimized, so that the delivery and controlled release of hydrophobic substances including high phenols are improved.

The present invention relates to a pharmaceutical composition for preventing or treating muscle diseases. Specifically, the elderberry extract or monosaccharide and amino acid combined compound disclosed by the invention inhibits apoptosis of muscle cells, inhibits expression of inflammatory cytokines, promotes secretion of testosterone and inhibits expression of amyotrophy marker protein and myogenesis inhibition protein, and shows an effect of recovering muscle in a sarcopenia animal model; therefore, the device can be effectively used in the treatment of muscle diseases.

The present invention provides methods for identifying and sequencing proteins, polypeptides, and amino acids, as well as compositions useful for them. [Solution] The present invention provides amino acid recognition molecules, such as amino acid-binding proteins and their fusion polypeptides, which differentially associate with different types of amino acids to generate detectable characteristic signatures that serve as indicators of the amino acid sequence of polypeptides. The present invention also provides amino acid recognition molecules that include a shielding element to enhance photostability during polypeptide sequencing reactions.

The invention provides a covalent small molecule compound and application and a pharmaceutical composition thereof, and relates to the technical field of pharmaceutical chemistry. The covalent small molecule compound provided by the invention can be combined with specific amino acid in the schistosome to form a covalent bond so as to inhibit the biological function of the schistosome. The covalent small molecule compound provided by the invention has a good killing effect on schistosomiasis and adult schistosomiasis, can be used for preparing drugs for treating schistosomiasis, and overcomes the technical problem of poor curative effect or ineffective treatment caused by drug resistance generated by long-term use of existing anti-schistosomiasis drugs; important scientific basis and research value are provided for research and development of novel anti-schistosomiasis drugs. The result of the embodiment shows that the insect reduction rate of the covalent small molecule compound provided by the invention can reach 82.35% (superior to praziquantel) in the juvenile insect stage, the insect reduction rate of the covalent small molecule compound in the adult stage can reach 63.63%, and the covalent small molecule compound shows relatively high activity of killing schistosome in vivo.

Provided herein are binding agents that selectively bind to individual monomer types (e.g., amino acid types) of a polymeric analyte (e.g., a peptide). The present disclosure provides methods for producing and, optionally, engineering binding agents. Such binding agents can be used for a variety of applications, including single-molecule peptide or protein sequencing.

There is provided a motif-specific, context-independent antibody that specifically binds a recurring, modified motif consisting of (i) at least one sumoylated lysine residue, and (ii) one or more degenerate amino acids bound by a peptide bond to said sumoylated lysine residue, said antibody specifically binding said motif in a plurality of non-homologous peptides or proteins within an organism in which it recurs. Also provided is a motif-specific, context-independent antibody that specifically binds a recurring, modified motif consisting of (i) a C-terminal aspartic acid residue, and (ii) one or more degenerate amino acids bound by a peptide bond to said C-terminal aspartic acid residue, said antibody specifically binding said motif in a plurality of non-homologous peptides or proteins within an organism in which it recurs.

N-terminal amino acid binding (NAAB) reagents are a tool for parallel, high-throughput proteomics. A fluorescently-labeled NAAB allows immobilized peptides to be identified by their N-terminal residues using single-molecule fluorescent microscopy, which enables novel proteomic analysis, like fluorescence-based next-generation protein sequence. Amino acid-specific binders are presented which bind to leucine at the N-terminus of peptides / polypeptides / proteins with high affinity and specificity, allowing detection of an N-terminal leucine with high confidence.

The invention provides a method for preparing soybean protein isolate gel by using amino acid composite TG enzyme. Preparing a protein solution, and stirring at room temperature; 40 U / g TG enzyme is added and fully mixed with the protein solution, then acidic amino acid with the concentration of 0.2%-1.0% (w / v) is added, the mixture is subjected to water bath for 1 h at the temperature of 40 DEG C and heated for 30 min in the water bath at the temperature of 95 DEG C, and the mixture is taken out, cooled in an ice-water bath for 10 min and stored overnight at the temperature of 4 DEG C. The specific amino acid is added into a soybean protein isolate system, and the cross-linking effect of the TG enzyme is combined, so that the elasticity and the hardness of the gel are remarkably enhanced, the water-retaining property and the water-holding capacity of the gel are improved, and the gel strength of the TG enzyme cross-linked soybean protein isolate gel is improved, so that the quality of the plant protein gel is improved.

Provided herein are novel amino acid binding proteins that recognize aspartate and / or glutamate in protein sequencing reactions; novel amino acid binding proteins that recognize arginine in protein sequencing reactions; and novel amino acid binding proteins that recognize glycine, alanine, and / or serine in protein sequencing reactions.

Provided herein are novel amino acid binding proteins that recognize aspartate and / or glutamate in protein sequencing reactions; novel amino acid binding proteins that recognize arginine in protein sequencing reactions; and novel amino acid binding proteins that recognize glycine, alanine, and / or serine in protein sequencing reactions.

The invention discloses an application of ganoderic acid A as an intestinal farnesic acid X receptor (FXR) inhibitor in preparation of a product for preventing and / or treating hyperlipidemia. Molecular docking software is used for predicting that ganoderic acid A can be combined with FXR and occupies an active site of the FXR, and a possible amino acid binding site is a TYR (tyrosine) 369 amino acid residue; the application of a Caco2 cell model proves that the ganoderic acid A can penetrate through a cell membrane to be directly combined with the FXR in the cell; a surface plasmon resonance result proves that ganoderic acid A can competitively inhibit the combination of an FXR endogenous agonist and FXR so as to inhibit the activity of the FXR endogenous agonist. By inhibiting the activity of FXR, the ganoderic acid A can significantly inhibit the expression of intestinal FXR target gene ileum bile acid binding protein, fibroblast growth factor 15 and small heterodimer partner, and effectively improve C57BL / 6J mouse hyperlipidemia induced by high fat diet.

To provide use of an elder berry extract for preventing or treating muscle diseases.SOLUTION: Provided is a pharmaceutical composition for preventing or treating a muscle disease, comprising, as an active ingredient, a monosaccharide and amino acid-bound compound or a pharmaceutically acceptable salt thereof, the monosaccharide and amino acid-bound compound being a compound represented by the following formula and the like, and the muscle disease being a disease caused by muscle loss.SELECTED DRAWING: Figure 17

The invention relates to the field of developing agents, in particular to a fingerprint developing agent and a developing method and application thereof. Wherein the fingerprint developing agent comprises a compound I and an organic solvent; the molecular structural formula of the compound I is I; wherein X is selected from CH3O <->,-CH3,-CH2CH3 or NO2; y is selected from CH3O <->,-CH3,-CH2CH3, NO2 or halogen; x and Y are the same or different. Compared with a traditional fingerprint display method, the compound can realize higher sensitivity and clearer imaging effect; and only protein and amino acid in fingerprints are combined to form a fluorescent product, and other substances (such as paper and the like) do not have a showing effect, so that highly selective fingerprint showing can be realized. And the method has a good application value in the actual development of the developing reagent.

Provided are antibody-drug conjugates containing a drug moiety attached to an antibody or fragment thereof having binding specificity to the wild-type human claudin 18.2 (CLDN18.2) protein. The antibody or the fragment thereof binds to the β3-β4 loop (residues 45-63 of SEQ ID NO: 30, NYQGLWRSCVRESSGFTEC) and the β5 strand (residues 169-172 of SEQ ID NO: 30, YTFG) of CLDN18.2.